Itralase SB 65mg Capsule contains Itraconazole, a broad-spectrum antifungal agent used for the treatment of various fungal infections. Itraconazole belongs to the triazole class of antifungals and works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itralase SB is indicated for the management of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other dermatophytic infections. The 65mg dosage form is designed for oral administration, ensuring adequate bioavailability and tissue penetration. It is particularly effective against infections caused by Candida species and dermatophytes. Itralase SB should be used under medical supervision, with dosing regimens tailored to the specific infection and patient condition. Common side effects may include gastrointestinal disturbances, headache, and rash, while serious adverse reactions are rare but may involve hepatotoxicity or cardiac effects. Caution is advised in patients with liver impairment or congestive heart failure. Drug interactions are significant due to itraconazole’s effect on cytochrome P450 enzymes; therefore, concurrent use with certain medications requires careful monitoring. Overall, Itralase SB 65mg Capsule is a potent antifungal option for effective management of fungal infections.